Home Companies Catalysts Deep Dives
Orpathys savolitinib PHASE3
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaOncology
Peak Sales Est$800M
Formulations[]
Companies
AZN (ORIGINATOR)50%
HUTCHMED (CO_DEVELOPER)50%
Mechanism: MET inhibitor
Expert: Selective MET tyrosine kinase inhibitor targeting MET exon 14 skipping mutations and MET amplification.
Everyday: Blocks MET protein that some lung cancers use to grow, especially when resistant to other treatments.
Targets: ["MET"]
Programs (1)
IndicationStageKey StudyRegional Status
NSCLC (MET+)APPROVEDINSIGHT[{"stage":"APPROVED","region":"CHINA","approval_date":"2020-06-19"}]
Notes
MET inhibitor. Hutchmed partnership.
Data from Supabase · Updated 2026-03-24